Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sodium Oxybate in Idiopathic Hypersomnia (SODHI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03597555
Recruitment Status : Recruiting
First Posted : July 24, 2018
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:
this study evaluates of the efficacy of sodium oxybate on excessive daytime sleepiness using Epworth sleepiness scale over 8 weeks compared to placebo

Condition or disease Intervention/treatment Phase
Idiopathic Hypersomnia Drug: Sodium Oxybate Oral Solution 500 MG/ML Drug: Placebos Phase 2 Phase 3

Detailed Description:

Bicentric, randomized, double-blind controlled study Outpatients aged from 18 to 60 years, suffering from current idiopathic hypersomnia (ICSD-3), recruited via medical consultations in the investigation centers Randomization in Xyrem or placebo arms after the inclusion visit,

1.Screening Period (up to 15 days), 2.Titration Period (up to 45 days), 3.Maintenance Period (minimum 15 days), 4.Safety Follow-Up Period (14 days)


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia
Actual Study Start Date : October 18, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Club Drugs

Arm Intervention/treatment
Experimental: Xyrem

Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.

First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.

First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal

Drug: Sodium Oxybate Oral Solution 500 MG/ML

First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.

First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.

First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal


Placebo Comparator: Placebos
Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
Drug: Placebos
Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid




Primary Outcome Measures :
  1. Epworth Sleepiness Scale (ESS) score at the end-point visit [ Time Frame: over 8 weeks ]
    Evaluation of difference in sleepiness with ESS between the 2 groups. ESS scores range from 0 to 24; there is a risk of pathological daytime sleepiness if score is > 10.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - Diagnostic of idiopathic hypersomnia (ICSD-3 criteria)
  • Age between 18 and 60 years-old
  • BMI between 18 and 35 kg/m2
  • MSLT: mean sleep latency (MSL) of ≤8 minutes and < 2 SOREMPs
  • Polysomnography recording: sleep efficiency > 90%, total sleep time ≥6 hours, AHI <10/hour, micro-arousals index <15/hour, PLM index associated with micro-arousals <10/hour.
  • Absence of sleep deprivation, assessed by actigraphy or sleep logs
  • ESS score ≥14 points
  • Written informed consent
  • National health insurance cover

Exclusion Criteria:

  • - Current alcohol intake or treatment with modafinil, amphetamine, methylphenidate, mazindol, pitolisant, neuroleptics, sedative hypnotics, barbiturates, general anesthetics, myorelaxants, other CNS depressants, antidepressants*, anxiolytic drugs, anticonvulsive therapy, topiramate, inhibitors of GHB dehydrogenase (i.e. valproate, ethosuximide, phenytoin), budipine, dopamine antagonist antiemetics (except domperidone), opioids, benzodiazepines, Z-drugs, MAO inhibitors, COMT inhibitors, or sedative antihistamines. If patient has received such therapy, a washout-period of at least 15 days, or equivalent to 5 half-lives of the drug, prior to the inclusion in the study is required before starting treatment in this study.

    *30 days for antidepressants

  • Previous intake of sodium oxybate
  • Succinic semialdehyde dehydrogenase deficiency, porphyria
  • Other central nervous system diseases: neurodegenerative diseases, seizure disorders or history of head trauma associated with loss of consciousness
  • Lifetime history of suicide attempt or suicidal ideation in the past 6 months, prior history of psychotic episodes, current or recent history of a major depressive disorder (DSM-V), Beck depression inventory (BDI) > 16 and/or item G> 0
  • History of chronic alcohol or drug abuse within the prior 12 months
  • Malignant neoplastic disease requiring therapy within 12 months prior to Visit 1 or clinically relevant
  • Heart failure, severe hypertension or other cardiovascular disease compromising the patient's wellbeing or ability to participate in this study
  • Renal or hepatic impairment Compromised respiratory function
  • Sleep-related breathing disorders (AHI ≥ 10/h)
  • No regular sleep at night: shift work or other continuous non-disease-related life conditions
  • Participation in another study of an investigational drug within the 28 days prior to Visit 1 or currently
  • Hypersensitivity to any of the components of the study medication
  • Pregnancy (βHCG positive) and breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03597555


Contacts
Layout table for location contacts
Contact: Yves DAUVILLIERS, Pr 33 4 67 33 63 61 y-dauvilliers@chu-montpellier.fr

Locations
Layout table for location information
France
University Hospital of Montpellier Recruiting
Montpellier, France
Contact: Yves Dauvilliers         
Contact: Elisa Evangelista         
Sponsors and Collaborators
University Hospital, Montpellier
Investigators
Layout table for investigator information
Principal Investigator: Yves DAUVILLIERS University Hospital, Montpellier

Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT03597555     History of Changes
Other Study ID Numbers: RECHMPL17_0375
First Posted: July 24, 2018    Key Record Dates
Last Update Posted: May 20, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Montpellier:
Idiopathic Hypersomnia

Additional relevant MeSH terms:
Layout table for MeSH terms
Disorders of Excessive Somnolence
Hypersomnolence, Idiopathic
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Pharmaceutical Solutions
Sodium Oxybate
Sodium Citrate
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Anticoagulants